[ad_1]
Amylyx Pharmaceuticals shares dropped more than 80% early Friday after the company said its ALS treatment Relyvrio failed a late-stage trial and may be pulled from the market.
[ad_2]
Source link
[ad_1]
Amylyx Pharmaceuticals shares dropped more than 80% early Friday after the company said its ALS treatment Relyvrio failed a late-stage trial and may be pulled from the market.
[ad_2]
Source link
© 2023 Newmexico Digital News